TrialAnnals of hematology2017

Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.

Muhamed Baljevic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.